|
2012 Journal Article Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective <i>BRAF</i> InhibitionZimmer, Lisa, Hillen, Uwe, Livingstone, Elisabeth, Lacouture, Mario E., Busam, Klaus, Carvajal, Richard D., Egberts, Friederike, Hauschild, Axel, Kashani-Sabet, Mohammed, Goldinger, Simone M., Dummer, Reinhard, Long, Georgina V., McArthur, Grant, Scherag, Andre, Sucker, Antje and Schadendorf, Dirk (2012). Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF Inhibition. Journal of Clinical Oncology, 30 (19), 2375-2383. doi: 10.1200/JCO.2011.41.1660 |
|
2012 Conference Publication Cutaneous side effects (cAE) of vemurafenib (V): Single-center cohort study of 28 metastatic melanoma (mM) patients (pts)Goldinger, Simone M., Rinderknecht, Jeannine Desiree, Belloni, Benedetta, Eggmann, Nina and Dummer, Reinhard (2012). Cutaneous side effects (cAE) of vemurafenib (V): Single-center cohort study of 28 metastatic melanoma (mM) patients (pts). 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, Jun 01-06, 2012. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. |
|
2012 Journal Article Cutaneous Lymphomas: Molecular Pathways Leading to New DrugsDummer, Reinhard, Goldinger, Simone M., Cozzio, Antonio, French, Lars E. and Karpova, Maria B. (2012). Cutaneous Lymphomas: Molecular Pathways Leading to New Drugs. Journal of Investigative Dermatology, 132 (3), 517-525. doi: 10.1038/jid.2011.370 |
|
2012 Journal Article Ultraviolet A and Photosensitivity during Vemurafenib TherapyDummer, Reinhard, Rinderknecht, Jeannine and Goldinger, Simone M. (2012). Ultraviolet A and Photosensitivity during Vemurafenib Therapy. New England Journal of Medicine, 366 (5), 480-481. doi: 10.1056/NEJMc1113752 |
|
2012 Journal Article First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07)von Moos, R., Seifert, B., Simcock, M., Goldinger, S. M., Gillessen, S., Ochsenbein, A., Michielin, O., Cathomas, R., Schlaeppi, M., Moch, H., Schraml, P. H., Mjhic-Probst, D., Mamot, C., Schoenewolf, N. and Dummer, R. (2012). First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Annals of Oncology, 23 (2), 531-536. doi: 10.1093/annonc/mdr126 |
|
2012 Journal Article Cutaneous Drug Eruptions Associated with the Use of New Oncological DrugsBelloni, Benedetta, Schoenewolf, Nicola, Rozati, Sima, Goldinger, Simone M. and Dummer, Reinhard (2012). Cutaneous Drug Eruptions Associated with the Use of New Oncological Drugs. Adverse Cutaneous Drug Eruptions, 97, 191-202. |
|
2011 Conference Publication Final results of single-agent phase II study using the inhibitor of purine nucleoside phosphorylase (PNP) in patients suffering from advanced primary cutaneous t-cell lymphomas (CTCL)Dummer, R., Duvic, M., Scarisbrick, J., Olsen, E., Goldinger, S., Hutchinson, K., Geskin, L., Illidge, T., Kim, Y., Giuliano, E. and Elder, J. (2011). Final results of single-agent phase II study using the inhibitor of purine nucleoside phosphorylase (PNP) in patients suffering from advanced primary cutaneous t-cell lymphomas (CTCL). MALDEN: WILEY-BLACKWELL. |
|
2011 Conference Publication Inhibition of the MEK-kinase pathway in advanced melanomaDummer, R., Goldinger, S., Turtschi, C., Gisler, S., Eggmann, N. and Rinderknecht, J. (2011). Inhibition of the MEK-kinase pathway in advanced melanoma. BASEL: KARGER. |
|
2011 Conference Publication An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastasesDummer, R., Rinderknecht, J., Goldinger, S. M., Wagner, I., Mitchell, L., Veronese, M. L., Nick, S., Hilfiker, P. and Gobbi, S. (2011). An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. doi: 10.1200/jco.2011.29.15_suppl.8548 |
|
2011 Journal Article The antibacterial substance, taurolidine in the second/third-line treatment of very advanced stage IV melanoma including brain metastases: results of a phase 2, open-label studyImhof, Laurence, Goldinger, Simone M., Baumann, Katrin, Schad, Karin, French, Lars E., Roethlisberger, Peter and Dummer, Reinhard (2011). The antibacterial substance, taurolidine in the second/third-line treatment of very advanced stage IV melanoma including brain metastases: results of a phase 2, open-label study. Melanoma Research, 21 (1), 80-83. doi: 10.1097/CMR.0b013e328341442d |
|
2010 Conference Publication Predictive and prognostic potential of angiogenic serum factors and circulating endothelial cells in metastatic melanoma patients receiving temozolamide plus bevacizumab (SAKK 50/07)Fuerstenberger, G., Boneberg, E., Simcock, M., Dummer, R., Goldinger, S. M., Michielin, O., Seifert, B., Ochsenbein, A. F., Schlaeppi, M. R. and von Moos, R. (2010). Predictive and prognostic potential of angiogenic serum factors and circulating endothelial cells in metastatic melanoma patients receiving temozolamide plus bevacizumab (SAKK 50/07). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. doi: 10.1200/jco.2010.28.15_suppl.8585 |
|
2010 Conference Publication First-line temozolomide (TEM) combined with bevacizumab (BEV) in metastatic melanoma (MM): A multicenter phase II trial (SAKK 50/07)Dummer, R., Michielin, O., Seifert, B., Ochsenbein, A. F., Cathomas, R., Schlaeppi, M. R., Simcock, M., Gillessen, S., Goldinger, S. M. and von Moos, R. (2010). First-line temozolomide (TEM) combined with bevacizumab (BEV) in metastatic melanoma (MM): A multicenter phase II trial (SAKK 50/07). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. doi: 10.1200/jco.2010.28.15_suppl.8521 |
|
2009 Journal Article Limited value of <SUP>18</SUP>F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanomaStrobel, K., Bode, B., Dummer, R., Veit-Haibach, P., Fischer, D. R., Imhof, L., Goldinger, S., Steinert, Hans C. and von Schulthess, G. K. (2009). Limited value of 18F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma. European Journal of Nuclear Medicine and Molecular Imaging, 36 (11), 1774-1782. doi: 10.1007/s00259-009-1175-0 |
|
2009 Conference Publication Temozolomide combined with bevacizumab in metastatic melanoma. A multicenter phase II trial (SAKK 50/07)Von Moos, R., Seifert, B., Ochsenbein, A., Cathomas, R., Schlaeppi, M., Gillessen, S., Schuller, J. C., Michielin, O., Goldinger, S. and Dummer, R. (2009). Temozolomide combined with bevacizumab in metastatic melanoma. A multicenter phase II trial (SAKK 50/07). 15th ECCO/34th ESMO Multidisciplinary Congress, Berlin Germany, Sep 20-24, 2009. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD. doi: 10.1016/S1359-6349(09)72059-2 |
|
2007 Journal Article Combination of 308-nm xenon chloride excimer laser and topical calcipotriol in vitiligoGoldinger, S. M., Dummer, R., Schmid, P., Burg, G., Seifert, B. and Lauchli, S. (2007). Combination of 308-nm xenon chloride excimer laser and topical calcipotriol in vitiligo. Journal of the European Academy of Dermatology and Venereology, 21 (4), 504-508. doi: 10.1111/j.1468-3083.2006.02016.x |
|
2006 Journal Article Excimer laser versus narrow-band UVB (311 nm) in the treatment of psoriasis vulgarisGoldinger, Simone Maria, Dummer, Reinhard, Schmid, Peter, Vavricka, Mareike Prinz, Burg, Guenter and Laeuchli, Severin (2006). Excimer laser versus narrow-band UVB (311 nm) in the treatment of psoriasis vulgaris. Dermatology, 213 (2), 134-139. doi: 10.1159/000093852 |
